Objectives The aim of this article was to review the current role of brain PET in the diagnosis
of Alzheimer dementia. The characteristic patterns of glucose metabolism on brain FDG-PET …

The concept of reserve has been proposed to account for the disjunction between the
degree of brain damage and its clinical outcome. This paper attempts to produce a coherent …

A person suspected of having Alzheimer's disease (AD) is clinically diagnosed for the
presence of principal biomarkers, especially misfolded amyloid-beta (Aβ) and tau proteins in …

Objective We wished to develop a highly selective positron emission tomography (PET)
imaging agent targeting PHF-tau in human Alzheimer's disease (AD) brains. Methods To …

Recent advances in noninvasive imaging modalities have opened endless opportunities for
molecular diagnostic and therapeutic procedures. The term “molecular imaging” is broadly …

Objective The most widely studied positron emission tomography ligand for in vivo β‐
amyloid imaging is 11C‐Pittsburgh compound B (11C‐PIB). Its availability, however, is …

The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PiB) binds
with high affinity to β-pleated sheet aggregates of the amyloid-β (Aβ) peptide in vitro. The in …

To date, most diagnostic imaging comparisons between amyloid labelling ligands and other
imaging modalities have been between the use of amyloid labelling ligand 11C Pittsburgh …

Objective: To compare brain β-amyloid (Aβ) burden measured with [11C] Pittsburgh
Compound B (PIB) PET in normal aging, Alzheimer disease (AD), and other dementias …

Background: Beta-amyloid (Aβ) plaques are the hallmark of Alzheimer disease (AD). A PET
imaging tracer that binds to Aβ plaques in vivo, N-methyl-[11C] 2-(4′-methylaminophenyl) …